A pilot study comparing different dose levels and administration schedules of interferon-α2b combined with epirubicin for prevention of recurrence in bladder cancer

Serretta,; Pavone, Carlo; Corselli, G.; Pavone‐Macaluso, M.

doi:10.1097/00001813-199205000-00005

Cited by 13 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The anti‐mitotic activity of IFN against human bladder carcinoma cell lines in vitro has been reported [ 9] and the enhancement of natural killer cell and T lymphocyte activity after intravesical administration of IFNα‐2b has been confirmed [ 10]. Intravesical IFNα‐2b has also been shown to increase concentrations of the urinary interleukins IL‐2 and IL‐4 [ 11]. Recently, Giannopoulos et al [ 12] found that IFNα‐2b receptors exist in bladder urothelium and that malignant cells express more of these receptors than do normal cells.…”

Section: Discussionmentioning

confidence: 99%

Efficacy of escalating doses of intravesical interferon α‐2b in reducing recurrence rate and progression in superficial transitional cell carcinoma

Giannakopoulos

Gekas

Alivizatos

et al. 1998

British Journal of Urology

View full text Add to dashboard Cite

Objective To compare the eBcacy of three diCerent doses groups A to D, respectively. The diCerences were statistically significant only between groups A and C of intravesical interferon a-2b P<0.001). The results were always in favour of the patients treated with the high dose, the only exception bimonthly for the next 4 months and thereafter monthly for 6 months. The patients were followed for being the diCerence between groups C and D (P= 0.026). No side-eCects of the drug were noted, nor 36 months. The four groups were compared for the number of recurrences (simple recurrence rate), prowas any adverse reaction reported from any patient. Conclusion These results show a significant advantage gression in stage, disease-free interval and recurrence rate per 100 patient-months.for adjuvant intravesical IFNa-2b treatment over TUR alone for the 36 months of follow up and indicate Results During the follow-up, 33 patients had recurrence (13, eight, seven and five in groups A to D, that IFNa-2b can modify the clinical course of superficial TCC at least in the short term. The appropriate respectively). The simple recurrence rate was 65% for group A, compared with 36% (P=0.06), 29% dose was apparently 80 MU, for although 40 MU was better than TUR alone, it was less eCective than 60 (P<0.05) and 22% (P<0.01) for groups B, C and D, respectively. The diCerences in simple recurrence rates MU and 80 MU; the 80 MU dose was slightly better than 60 MU and thus this regimen is recommended. between the groups treated with IFNa-2b were not statistically significant. Eleven patients experienced Keywords Interferon, transitional cell carcinoma, immunotherapy, progression, outcome progression in stage, with six, three, one and one in gression occurs in 5-30% of all cases and up to 80% of

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of escalating doses of intravesical interferon α‐2b in reducing recurrence rate and progression in superficial transitional cell carcinoma

Giannakopoulos

Gekas

Alivizatos

et al. 1998

British Journal of Urology

View full text Add to dashboard Cite

show abstract

“…The optimal dose and schedule of interferon remains to be defined. Combination treatment of interfer on with cytostatics intravesically is scarcely investigated and the results are not yet conclusive [43][44][45], TUR alone when adjuvant intravesical instillation of cytotoxic agents or immunomodulators is added. Patient characteristics are important factors in determining which patients and how far they might benefit from adju vant treatment (table 2).…”

Section: Intravesical Treatmentmentioning

confidence: 99%

Diagnosis and Treatment of Superficial Transitional Cell Carcinoma of the Bladder: Facts and Perspectives

Kh¹

1997

Eur Urol

View full text Add to dashboard Cite

“…Encouraging results have been reported by a number of investigators [68][69][70]; once again, the higher dose of IFN seemed to be more effective.…”

Section: Bladder Cancermentioning

confidence: 63%

Interferons in the Therapy of Solid Tumors

Agarwala

Kirkwood

1994

Oncology

View full text Add to dashboard Cite

Interferons, a group of naturally occurring proteins, possess potent immunological effects. The availability of large amounts of purified interferon through recombinant DNA technology has led to the testing of these agents against a number of tumor types. Interferon-α has been the most widely studied. The most encouraging results have been observed in the treatment of melanoma among nonhematological neoplasms, and in the locoregional treatment of other tumor types. It is hoped that further research into the use of the interferons, both singly and in combination with chemotherapy and other immunological agents, will lead to a better elucidation of their therapeutic role against cancer. In this article, the use of interferons in the treatment of solid tumors is reviewed.

show abstract

A pilot study comparing different dose levels and administration schedules of interferon-α2b combined with epirubicin for prevention of recurrence in bladder cancer

Cited by 13 publications

References 0 publications

Efficacy of escalating doses of intravesical interferon α‐2b in reducing recurrence rate and progression in superficial transitional cell carcinoma

Efficacy of escalating doses of intravesical interferon α‐2b in reducing recurrence rate and progression in superficial transitional cell carcinoma

Diagnosis and Treatment of Superficial Transitional Cell Carcinoma of the Bladder: Facts and Perspectives

Interferons in the Therapy of Solid Tumors

Contact Info

Product

Resources

About